More than 76,000 people in the US are diagnosed each year with renal cell carcinoma (RCC). Increased approval of oral therapies and recent guideline updates both elevate the pharmacist’s important role to support patients in managing their treatment. Learn about pathophysiology, assessments, diagnosis, and treatment algorithm updates so you can appropriately manage patients with RCC.

Upon successful completion of this application-based CPE course, pharmacists should be able to:
1. List the signs, symptoms, and diagnostic and staging criteria of renal cell carcinoma
2. Apply guideline-based treatment algorithms to persons with renal cell carcinoma
3. Develop monitoring plans for persons with renal cell carcinoma and medications used to treat renal cell carcinoma
4. Formulate evidence-based recommendations for persons with renal cell carcinoma
5. Discuss the role of the pharmacy team in the patient journey for persons with renal cell carcinoma 

Kelly Brunk, PharmD, BCOP
Clinical Pharmacist
The University of Kansas Health System

Kelly Brunk does not report any actual or potential conflicts of interest in relation to this continuing pharmacy education course.

Note: Off-label use will be discussed in this course. 

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: October 1, 2021
Planned Expiration Date: October 1, 2024

Copyright 2021, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.